CPDR BACKGROUND

In 1992, amid the growing prevalence of prostate cancer and controversy over the optimal
treatment for it, Congress enacted Public Law 102-172 to establish the Center for Prostate Disease
Research (CPDR) with the mission of studying prostate cancer and prostate disease in the US
Military Health Care System. The law designated the authority to the Uniformed Services
University of the Health Sciences (USU) to create and administer CPDR, in coordination with the
USU-affiliated Henry M. Jackson Foundation for the Advancement of Military Medicine (HJF).
CPDR has received funding from the office of Congressionally Directed Medical Research
Programs (CDMRP) of the US Army Medical Research and Materiel Command (USAMRMC). In
2010, CPDR was recognized as a Department of Defense (DoD)-Center of Excellence for multidisciplinary
translational research in prostate cancer and the center is now funded under the DoD,
USU-School of Medicine (SoM).

The CPDR integrates a multidisciplinary approach to prostate cancer and continues to make
great strides in clinical and basic sciences research for improving the entire spectrum of care to
include diagnosis, treatment, management, and follow-up for patients with prostate cancer. CPDR's
strategy is to focus investigators on potential breakthrough basic science and clinical research
within its three major research programs - Clinical Program, Basic Science Program, and
Multicenter National Database - and maintain the core support requirements for all programs.

COL David G. McLeod, MD, MC, USA (Ret.), is an internationally renowned urologic
oncologist at the Walter Reed National Military Medical Center (WRNMMC) and a professor in
the USUHS SoM Department of Surgery. Dr. McLeod serves as the Director of the CPDR. Shiv
Srivastava, PhD, is an internationally recognized cancer molecular biologist and a professor in the
USU SoM Department of Surgery. Dr. Srivastava is the CPDR Co-Director. CPDR's senior
leadership also includes Isabell A. Sesterhenn, MD, Director, CPDR-Genitourinary Pathology
collaborations, a distinguished genitourinary pathologist at the Joint Pathology Center; LTC
Inger Rosner, MD, MC, USA, Associate Director, Clinical Research Program, a leading
urologic oncologist at WRNMMC; Albert Dobi, PhD, Associate Director, Basic Science Research
Program, an established molecular biologist with transcription factor and hormonal mechanisms
expertise; Jennifer Cullen, PhD, Director, Epidemiology Research and Multicenter National
Database, a cancer epidemiologist with a strong track record in racial disparity research; Gyorgy
Petrovics, PhD, Assistant Director, Basic Science Research Program, an experienced cancer
molecular biologist with translational research expertise; Taduru Sreenath, PhD, Assistant Director,
Basic Science Research Program, an established investigator with engineered mouse model
expertise; and Mr. Adam Dimke, Program Administrative Director with management experience in DoDsupported
multidisciplinary medical research programs.

To accommodate the needs of its increasingly robust basic science research efforts, in 1999
CPDR expanded from its laboratories within the Department of Surgery at USU to an 18,000-
square-foot, stand-alone prostate disease research facility containing laboratory and administrative
space in Rockville, MD. This outstanding facility continues to provide state-of-the-art infrastructure
for the Basic Science Research, Multicenter National Database and Administration
programs of the CPDR supported by a dedicated team of cancer cell and molecular biologists,
epidemiologist, a bio-statistician, medical- and bio-informatics specialists and administrative staff.
CPDR Basic Science Research Program has been credited with many ground-breaking discoveries
leading to a better understanding of the prostate cancer biology and development of promising
biomarkers. The CPDR facility in Rockville has also been the hub of state-of-the-art prostate cancer
research training experience to a large number of short-term and long-term researchers including
post-doctoral fellows, urology residents, visiting scientists, medical and graduate students, and
summer interns. CPDR Rockville serves as the headquarters of the Multicenter National Database
under the USU SoM. During the last two decades, eight DoD medical centers and one civilian site
have contributed data from more than 25,845 patients to the CPDR Database. Currently CPDR
maintains active operations at WRNMMC, Naval
Medical Center-San Diego (NMCSD), Madigan Army Medical Center (MAMC), Tripler Army
Medical Center (TAMC), and Virginia Mason Medical Center. Database sites have been valuable to
CPDR for the multi-center clinical and epidemiologic and translational investigations conducted by
CPDR investigators and collaborators.

In August 2000, CPDR opened a fully dedicated prostate cancer center at the Walter Reed
Army Medical Center (WRAMC). The 13,000-square-foot facility accommodated the state-of-theart
clinical research, innovative clinical trials and a comprehensive biospecimen bank supported by
dedicated and integrated efforts of urologic-oncologists, physician assistants, clinical research
coordinators, medical technologists, and a full-time PhD nurse researcher in education. The prostate
cancer center also supports two weekly multidisciplinary clinics with specialists from urology,
radiation oncology, and medical oncology as well as comprehensive patient education and support
activity. As part of the Base Realignment and Closure (BRAC) process that began in 2005, the
WRAMC-CPDR Clinical Research Program moved to a new location. The new state-of-the-art
CPDR Clinical Research Program opened at WRNMMC, formerly known as the National Naval
Medical Center, in Bethesda, MD, on August 23, 2011. The CPDR-Clinical Research Program is
located on the 3rd floor of Building 19 of WRNNMC. The new state-of-the-art, 4,000-square-foot
facility at WRNMMC continues to facilitate the clinical and research activities formerly conducted
at WRAMC to ensure military beneficiaries suffering from prostate disease are provided
exceptional care.